Amgen's Prolia and Evenity for the treatment of osteoporosis continue to show sales growth. Prolia and Evenity led Amgen's performance, generating sales of KRW 2 trillion in Q3. Analysis suggests that sequential therapy, using Evenity followed by Prolia for the treatment of osteoporosis with high-risk fractures, has been widely used, and it has led to continued increases in sales.

Sources said on November 6th, Amgen's sales in Q3 were US$ 8.50 billion (approximately KRW 11.72 trillion), up 23.1% year-over-year (YoY). Operating profit for the same period was US$ 2.047 billion, up 1.3% from 2022.

Prolia generated the highest sales among Amgen's products. Prolia's sales in Q3 were US$1.045